Pharmacokinetics of factor VIII and factor IX.
A survey of principal pharmacokinetic (PK) studies on factor VIII (FVIII) and factor IX (FIX) plasma- and rDNA-derived concentrates, analysed by means of the PKRD program, has been performed. Notwithstanding the accurate definition of the study design, released in 1991 by the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (SSC-ISTH), a large variability of PK parameters has been pointed out. In the majority of the PK studies, the size of the population is small. In this situation, a careful individualization of haemophilia therapy is strongly recommended. The tailored prediction of loading and maintenance dosages and the need for strict control of trough FVIII/IX levels are mandatory not only to decrease the risk of bleeds but also to spare financial resources. Recently, the old problem of FVIII assay standardization has again become a concern among physicians, especially after the introduction of B-domain deleted rFVIII concentrate. The discrepancies between the widely used one-stage clotting assay and the chromogenic substrate assay seem to be solved by the introduction of a product-specific laboratory standard.
Morfini
M
M
Regional Reference Centre for Inherited Coagulopathies, Azienda Ospedaliera Careggi, Firenze, Italy. m.morfini@dfc.unifi.it
D018592:Cross-Over Studies; D005164:Factor IX / Q000493:pharmacokinetics*; D005169:Factor VIII / Q000493:pharmacokinetics*; D006467:Hemophilia A / Q000378:metabolism / Q000517:prevention & control; D006801:Humans; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX